Naoki Furuya is an expert in Oncology at St. Marianna University School of Medicine (Japan). As of October 2026, ScienceLeadR ranks Naoki Furuya in the top 1% of experts worldwide for Lung Neoplasms and Thoracic Neoplasms. Naoki Furuya has authored 203 publications, the most recent in 2026. SLR score: 627 (community average: 125). How the SLR is computed.

LeadR Profile

627 ScienceLeadR Reputation 627
Network Map

Oncology

Subspecialties: Pulmonology - Public Health - Biochemistry

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2010 - 2026

Source: PubMed

St. Marianna University School of Medicine

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 203

Citations

Citations: 2 427 1st author: 19 Last author: 1 Unique author: 4


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Effect of Intratumoral PD-L1 Expression on Treatment Efficacy of ALK Tyrosine Kinase Inhibitors for Advanced or Recurrent ALK-Positive Non-small Cell Lung Cancer.
PMID 42932091 — treatment outcome, cells, lung, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, protein-tyrosine kinases, tyrosine, therapeutics
Med Oncol20260
Clinicopathological Features of DLL3 Expression and T-Cell Infiltration in LCNEC: Insights From Pathology and Clinical Response to Tarlatamab.
PMID 42876375 — cells, lung, thoracic neoplasms, cold temperature, neoplasms, pathology, t-lymphocytes, prognosis
Thorac Cancer20260
Osimertinib vs. erlotinib combined with an angiogenesis inhibitor in EGFR-mutated non-small cell lung cancer with malignant pleural effusion: a retrospective cohort study.
PMID 42723906 — cells, lung, pleural effusion, angiogenesis inhibitors, neoplasms, cohort studies, carcinoma, non-small-cell lung, exons, lung neoplasms, small cell lung carcinoma, therapeutics, mutation, pleural effusion, malignant, angiogenesis
Transl Lung Cancer Res20260
Enozertinib in EGFR Exon 20ins mutants: a game changer for CNS metastases, or a temporary conquest?
PMID 42723841 — exons, neoplasm metastasis
Transl Lung Cancer Res20260
ERRATUM: Impact of TTF-1 Expression on the Prognostic Prediction of Patients with Non-Small Cell Lung Cancer with PD-L1 Expression Levels of 1% to 49%, Treated with Chemotherapy vs. Chemoimmunotherapy: A Multicenter, Retrospective Study.
PMID 42681797 — cells, lung, retrospective studies, neoplasms, carcinoma, non-small-cell lung, drug therapy, lung neoplasms, small cell lung carcinoma, chemotherapy
Cancer Res Treat20260

LeadR Networks

Main global connection map